Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead

Abstract

The knowledge that the body possesses natural defenses to combat cancer existed long before the modern period, with multiple anecdotal reports of tumors miraculously disappearing, sometimes spontaneously or after a febrile or infectious episode. Spontaneous tumor regression of untreated malignant tumors is currently a well-accepted albeit rare phenomenon, and it is recognized that immunosuppression is associated with a higher cancer risk. The treatment of bladder carcinoma by intravesical administration of live attenuated Bacillus Calmette-Guérin bacteria was shown to be very effective in 1976 and is now standard treatment. Effective immunity against cancer involves complex interactions between the tumor, the host, and the environment. Cancer immunotherapy uses various strategies to augment tumor immunity and represents a paradigm shift in treating cancer, since attention has become more focused on the “biologic passport” of the individual tumor rather than the site of origin of the tumor. The different types of cancer immunotherapies discussed here include biologic modifiers, such as cytokines and vaccines, adoptive cell therapies, oncolytic viruses, and antibodies against immune checkpoint inhibitors, such as the co-inhibitory T-cell receptor PD-1 and one of its ligands, programmed death-ligand 1.

Keywords

Cancer immunotherapy / immune checkpoint inhibitors / PD-1 / programmed death-ligand 1 / cytotoxic T-lymphocyte-associated antigen-4 / adoptive cell therapy / cancer vaccines / oncolytic viruses / history of cancer immunology

References

[1] Gay P, Prasad V. Few people actually benefit from "breakthrough" cancer immunotherapy. Available from: https://www.statnews.com/2017/03/08/immunotherapy-cancer-breakthrough/. [Last accessed on 30 Oct 2017]

[2] Schadendorf D,Robert C,Margolin K,Patt D,Berman DM.Pooled analysis of long-term survival data from phase ii and phase iii trials of ipilimumab in unresectable or metastatic melanoma..J Clin Oncol2015;33:1889-94 PMCID:PMC5089162

[3] Luke JJ,Ribas A.Targeted agents and immunotherapies: optimizing outcomes in melanoma..Nat Rev Clin Oncol2017;14:463-82

[4] ASCO Daily News. Available from: https://am.asco.org/checkmate-067-longer-follow-shows-melanoma-pfs-still-better-combo-nivolumabipilimumab. [Last accessed on 30 Oct 2017]

[5] Postow MA,Pavlick AC,Grossmann K,Linette GP,Giguere JK,Shaheen M,Minor D,Taylor M,Rollin LM,Gagnier P,Hodi FS.Nivolumab and ipilimumab versus ipilimumab in untreated melanoma..N Engl J Med2015;372:2006-17

[6] Langer CJ,Borghaei H,Patnaik A,Gentzler RD,Stevenson JP,Panwalkar A,Gubens M,Awad MM,Ge Y,Gandhi L.Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a harmacody, phase 2 cohort of the open-label KEYNOTE-021 study..Lancet Oncol2016;17:1497-508

[7] Patel SH,Cohen RB.Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors..Transl Lung Cancer Res2017;6:186-95 PMCID:PMC5420531

[8] Chida K,Shomura H,Hattori A,Taketomi A.Spontaneous regression of transverse colon cancer: a case report..Surg Case Rep2017;3:65 PMCID:PMC5423878

[9] Challis GB.The spontaneous regression of cancer. A review of cases from 1900 to 1987..Acta Oncol1990;29:545-50

[10] Kucerova P.Spontaneous regression of tumour and the role of microbial infection - possibilities for cancer treatment..Anticancer Drugs2016;27:269-77 PMCID:PMC4777220

[11] Busch W.Aus der Sitzung der medicinischen Section vom 13 November 1867..Berlin Klin Wochenschr1868;5:137(in German).

[12] Fehleisen F.Ueber die Züchtung der Erysipelkokken auf künstlichem Nährboden und ihre übertragbarkeit auf den Menschen..Dtsch Med Wochenschr1882;8:553-4. (in German)

[13] Oelschlaeger TA.Bacteria as tumor therapeutics?.Bioeng Bugs2010;1:146-7 PMCID:PMC3026455

[14] Coley WB.The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases..Am J Medical Sciences1893;105:487-511

[15] Coley WB.The treatment of sarcoma with the mixed toxins of erysipelas and Bacillus prodigiosus..Boston Med Surg J1908;158:175-82

[16] Parish CR.Cancer immunotherapy: the past, the present and the future..Immunol Cell Biol2003;81:106-13

[17] Morales A,Bruce AW.Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors..J Urol1976;116:180-3

[18] Old LJ,Benacerraf B.Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse..Nature1959;184:291-2

[19] Carswell EA,Kassel RL,Fiore N.An endotoxin-induced serum factor that causes necrosis of tumors..Proc Natl Acad Sci U S A1975;72:3666-70 PMCID:PMC433057

[20] Larson C,Scicinski J,Stirn M,Reid TR.Going viral: a review of replication-selective oncolytic adenoviruses..Oncotarget2015;6:19976-89 PMCID:PMC4652981

[21] Abbas AK, Lichtman AH, Pillai S. Properties and Overview of Immune Responses. In: Cellular and Molecular Immunology, 9th edition. Amsterdam: Elsevier; 2017. pp. 1–11.

[22] Brodin P.Human immune system variation..Nat Rev Immunol2017;17:21-9 PMCID:PMC5328245

[23] Loeb LA.Human cancers express mutator phenotypes: origin, consequences and targeting..Nat Rev Cancer2011;11:450-7 PMCID:PMC4007007

[24] Lindahl T.Quality control by DNA repair..Science1999;286:1897-905

[25] Stoler DL,Basik M,Rodriguez-Bigas MA,Anderson GR.The onset and extent of genomic instability in sporadic colorectal tumor progression..Proc Natl Acad Sci U S A1999;96:15121-6 PMCID:PMC24783

[26] Vesely MD,Schreiber RD.Natural innate and adaptive immunity to cancer..Annu Rev Immunol2011;29:235-71

[27] Wang RF.Immune targets and neoantigens for cancer immunotherapy and precision medicine..Cell Res2017;27:11-37

[28] Childs RW.Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens..Nat Rev Drug Discov2015;14:487-98

[29] Haabeth OA,Fauskanger M,Lorvik KB,Omholt H,Dembic Z,Bogen B.How do CD4(+) T cells detect and eliminate tumor cells that either lack or express MHC class II molecules?.Front Immunol2014;5:174 PMCID:PMC3995058

[30] Burnet M.Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications..Br Med J1957;1:841-7 PMCID:PMC1973618

[31] Burnet FM.The concept of immunological surveillance..Prog Exp Tumor Res1970;13:1-27

[32] Thomas L.Lawrence HS.Discussion.Cellular and Humoral Aspects of the Hypersensitive States1959;New York, NYHoeber-Harper529-32

[33] Dunn GP,Ikeda H,Schreiber RD.Cancer immunoediting: from immunosurveillance to tumor escape..Nat Immunol2002;3:991-8

[34] Tsukahara T,Torigoe T,Nakazawa E,Nabeta Y,Kaya M,Wada T,Sato N.Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5..Cancer Sc2006;97:1374-80

[35] Sharma P,Wargo JA.Primary, adaptive, and acquired resistance to cancer immunotherapy..Cell2017;168:707-23

[36] van der Bruggen P,Chomez P,De Plaen E,Knuth A.A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma..Science1991;254:1643-7

[37] Hanahan D.Hallmarks of cancer: the next generation..Cell2011;144:646-74

[38] Kitamura T,Pollard JW.Immune cell promotion of metastasis..Nat Rev Immunol2015;15:73-86 PMCID:PMC4470277

[39] McAllister SS.The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis..Nat Cell Biol2014;16:717-27

[40] Garrido F,Doorduijn EM,van Hall T.The urgent need to recover MHC class I in cancers for effective immunotherapy..Curr Opin Immunol2016;39:44-51 PMCID:PMC5138279

[41] Chen DS.Elements of cancer immunity and the cancer-immune set point..Nature2017;541:321-30

[42] Kager L,Bielack S.Review of mifamurtide in the treatment of patients with osteosarcoma..Ther Clin Risk Manag2010;6:279-86 PMCID:PMC2893760

[43] Gardner TA,Hahn NM.Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer..Hum Vaccin Immunother2012;8:534-9

[44] Kaiser J.Personalized tumor vaccines keep cancer in check..Science2017;356:122

[45] Speil C.Vaccines and vaccine adjuvants as biological response modifiers..Infect Dis Clin North Am2011;25:755-72

[46] Fuge O,Allchorne P.Immunotherapy for bladder cancer..Res Rep Urol2015;7:65-79 PMCID:PMC4427258

[47] Choi AH,Fong Y.From benchtop to bedside: a review of oncolytic virotherapy..Biomedicines2016;4:E18 PMCID:PMC5344257

[48] Guillerey C,Smyth MJ.Targeting natural killer cells in cancer immunotherapy..Nat Immunol2016;17:1025-36

[49] Jinek M,Fonfara I,Doudna JA.A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity..Science2012;337:816-21

[50] Cong L,Cox D,Barretto R,Hsu PD,Jiang W,Zhang F.Multiplex genome engineering using CRISPR/Cas systems..Science2013;339:819-23 PMCID:PMC3795411

[51] Cyranoski D.CRISPR gene-editing tested in a person for the first time..Nature2016;539:479

[52] Xin G,Jing W,Joshi NS,Cuia W.Pathogen boosted adoptive cell transfer immunotherapy to treat solid tumors..Proc Natl Acad Sci U S A2017;114:740-5 PMCID:PMC5278465

[53] Offord C. Making car T-cell therapy safer. The Scientist 2017; April 1. Available from: http://www.the-scientist.com/?articles.view/articleNo/48973/title/Making-CAR-T-Cell-Therapy-Safer/. [Last accessed on 30 Oct 2017]

[54] FDA News Release. FDA approval brings first gene therapy to the United States. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm. [Last accessed on 30 Oct 2017]

[55] Gallimore A,Godkin A,Plückthun A,Hengartner H.Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes..J Exp Med1998;187:1383-93 PMCID:PMC2212278

[56] Catakovic K,Neureiter D.T cell exhaustion: from pathophysiological basics to tumor immunotherapy..Cell Commun Signal2017;15:1 PMCID:PMC5225559

[57] Mognol GP,Wong V,Togher S,Hogan PG,Trifari S.Exhaustion-associated regulatory regions in CD8+ tumor-infiltrating T cells..Proc Natl Acad Sci U S A2017;114:E2776-85 PMCID:PMC5380094

[58] Wherry EJ.Molecular and cellular insights into T cell exhaustion..Nat Rev Immunol2015;15:486-99 PMCID:PMC4889009

[59] Schietinger A.Tolerance and exhaustion: defining mechanisms of T cell dysfunction..Trends Immunol2014;35:51-60 PMCID:PMC3946600

[60] Tsai HF.Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets..J Biomed Sci2017;24:35 PMCID:PMC5445514

[61] Brunet JF,Luciani MF,Suzan M,Golstein P.A new member of the immunoglobulin superfamily—CTLA-4..Nature1987;328:267-70

[62] Krummel MF.CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation..J Exp Med1995;182:459-65

[63] Ishida Y,Shibahara K.Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death..EMBO J1992;11:3887-95 PMCID:PMC556898

[64] Dong H,Salomao DR,Hirano F,Roche PC,Zhu G,Lennon VA,Chen L.Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion..Nat Med2002;8:793-800

[65] Freeman GJ,Iwai Y,Chernova T,Fitz LJ,Okazaki T,Horton HF,Carter L,Bowman MR,Collins M,Honjo T.Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation..J Exp Med2000;192:1027-34 PMCID:PMC2193311

[66] Latchman Y,Chernova T,Borde M,Iwai Y,Brown JA,Greenfield EA,Boussiotis VA,Carreno BM,Nishimura H,Honjo T,Freeman GJ.PD-L2 is a second ligand for PD-1 and inhibits T cell activation..Nat Immunol2001;2:261-8

[67] Buchbinder EI.CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition..Am J Clin Oncol2016;39:98-106 PMCID:PMC4892769

[68] Yearley JH,Yu N,Murphy E,Lunceford J,Chow LQM,Handa M,McClanahan T.PD-L2 expression in human tumors: relevance to Anti-PD-1 therapy in cancer..Clin Cancer Res2017;23:3158-67

[69] Fife BT.Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways..Immunol Rev2008;224:166-82

[70] Pardoll DM.The blockade of immune checkpoints in cancer immunotherapy..Nat Rev Cancer2012;12:252-64 PMCID:PMC4856023

[71] Chen DS.Oncology meets immunology: the cancer-immunity cycle..Immunity2013;39:1-10

[72] Leach DR,Allison JP.Enhancement of antitumor immunity by CTLA-4 blockade..Science1996;271:1734-6

[73] Mino-Kenudson M.Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?.Cancer Biol Med2016;13:157-70 PMCID:PMC4944542

[74] Ritprajak P.IIntrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma..Oral Oncol2015;51:221-8

[75] Haanen JBAG,Robert C,Peters S,Jordan K.Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up..Ann Oncol2017;28:iv119-42

[76] Kroschinsky F,von Bonin S,Kochanek M,Schellongowski P.New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management..Crit Care2017;21:89 PMCID:PMC5391608

[77] Champiat S,Barreau E,Berdelou A,Cauquil C,Collins M,Ederhy S,François H,Le Pavec J,Mateus C,Samuel D,Robert C,Marabelle A.Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper..Ann Oncol2016;27:559-74

[78] Michot M,Champiat S,Carbonnel F,Berdelou A,Hollebecque A,Fuerea A,Gazzah A,Amellal N,Noel N,Mateus C,Soria JC,Lambotte O.Immune-related adverse events with immune checkpoint blockade: a comprehensive review..Eur J Cancer2016;54:139-48

[79] Robert C,Long GV,Grob JJ,Daud A,McNeil C,Larkin J,Neyns B,Hamid O,Shapira-Frommer R,Zhou H,Ebbinghaus S.Pembrolizumab versus ipilimumab in advanced melanoma..N Engl J Med2015;372:2521-32

[80] Naidoo J,Woo KM,Halpenny D,Chaft JE,Callahan MK,Rosenberg J,Rudin CM,Hou X,Albano M,Leduc C,Harris B,Guminski AD,Kong BY,Postow MA,Hellmann MD.Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy..J Clin Oncol2017;35:709-17 PMCID:PMC5559901

[81] Suntharalingam G,Ward S,Castello-Cortes A,Panoskaltsis N.Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412..N Engl J Med2006;355:1018-28

[82] Attarwala H.TGN1412: from discovery to disaster..J Young Pharm2010;2:332-6 PMCID:PMC2964774

[83] Iwai Y,Chamoto K.Cancer immunotherapies targeting the PD-1 signaling pathway..J Biomed Sci2017;24:26 PMCID:PMC5381059

[84] Burstein HJ,Aragon-Ching JB,Chiorean EG,De Groot JF,DuBois SG,Epstein AS,Jones JA,Miksad RA,Sabel MS,Schuchter LM,Winkfield KM,Dizon DS.Clinical cancer advances 2017: annual report on progress against cancer from the American Society of Clinical Oncology..J Clin Oncol2017;35:1341-67

[85] Sharma P.Immune checkpoint therapy and the search for predictive biomarkers..Cancer J2016;22:68-72 PMCID:PMC4847150

[86] Hegde PS,Evers S.The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition..Clin Cancer Res2016;22:1865-74

[87] Gajewski TF.The next hurdle in cancer immunotherapy: overcoming the non-T-cell-inflamed tumor microenvironment..Semin Oncol2015;42:663-71 PMCID:PMC4555998

[88] Schumacher TN.Neoantigens in cancer immunotherapy..Science2015;348:69-74

[89] Rizvi NA,Snyder A,Makarov V,Lee W,Wong P,Miller ML,Moreira AL,Bruggeman C,Zappasodi R,Sander C,Merghoub T,Schumacher TN.Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer..Science2015;348:124-8 PMCID:PMC4993154

[90] Passardi A,Valgiusti M.Immune checkpoints as a target for colorectal cancer treatment..Int J Mol Sci2017;18:E1324 PMCID:PMC5486145

[91] Leal AD,Finnes HD.Response to pembrolizumab in patients with mismatch repair deficient (dMMR) colorectal cancer (CRC)..J Clin Oncol2017;35:3558

[92] Wargo JA,Spencer C,Reuben A,Tetzlaff MT,Hwu P,Glitza IC,Patel SP,Davies MA,Futreal A,Allison JP.Association of the diversity and composition of the gut microbiome with responses and survival (PFS) in metastatic melanoma (MM) patients (pts) on anti-PD-1 therapy..J Clin Oncol2017;35:3008

[93] Derosa L,Enot D,Massard C,Fizazi K,Zitvogel L.Impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors..J Clin Oncol2017;35:abstract 462

[94] Mbongue JC,Torrez TW,Firek AF.The role of indoleamine 2, 3-dioxygenase in immune suppression and autoimmunity..Vaccines (Basel).2015;3:703-29 PMCID:PMC4586474

[95] Siu LL. BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamics activity, alone and in combination with nivolumab (Nivo) in advanced cancers in a phase I/IIa trial. Presented at: 2017 AACR Annual Meeting; April 1-5, 2017; Washington, DC. Abstract CT116. Available from: http://www.aacr.org/Documents/AACR2017_ProgramGuide.pdf#search=CT116. [Last accessed on 30 Oct 2017]

[96] Patel SJ,Kishton RJ,Vodnala SK,Gartner JJ,Steinberg SM,Merchant AS,Chichura A,Tran E,Sukumar M,Day CP,Feldman S,Zhang F.Identification of essential genes for cancer immunotherapy..Nature2017;548:537-42

[97] Beasley D. The cost of cancer: new drugs show success at a steep price. Reuters 2017, April 3. Available from: http://www.reuters.com/article/usa-healthcare-cancer-costs/rpt-the-cost-of-cancer-new-drugs-show-success-at-a-steep-price-idUSL2N1HB06W. [Last accessed on 30 Oct 2017]

[98] Shelley S. Oncology: a new era in therapies; same cost concerns.Pharmaceutical Commerce. 2016, May 31. Available from: http://pharmaceuticalcommerce.com/brand-marketing-communications/oncology-new-era-therapies-cost-concerns/. [Last accessed on 30 Oct 2017]

[99] FDA News Release. FDA approves first cancer treatment for any solid tumor with a specific genetic feature. Available from: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm560167.htm. [Last accessed on 30 Oct 2017]

[100] Allison JP. Unleashing the immune system to combat cancer. 2015 Lasker-DeBakey Clinical Medical Research Award. Available from: http://www.laskerfoundation.org/awards/show/unleashing-immune-system-combat-cancer/. [Last accessed on 30 Oct 2017]

[101] Allison JP,Bloch D.Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody..J Immunol1982;129:2293-300

[102] Metchnikoff E.Untersuchungen ueber die mesodermalen phagocyten einiger wirbeltiere..Biologisches Centralblatt1883;3:560-5(in German).

[103] Von Behring E.Ueber das Zustandekommen der Diphtherie-Immunität und der Tetanus-Immunität bei Thieren..Dtsch Med Wschr1890;16:1113-4. (in German)

[104] Bordet J.Les Leucocytes et les propriétés du sérum ches les vaccinés..Ann de l'Inst Pasteur1895;ix:462-506(in French).

[105] Ehrlich P.Die Wertbesmessung des Diphterieilserums und deren theoretische Grundlagen..Klinische Jahrbuch1897;6:299-326(in German).

[106] Landsteiner K.über Agglutinationserscheinungen normalen menschlichen Blutes..Wien Klin Wochenschr1901;14:1132-34(in German).

[107] Jensen CO. Experimental studies on cancer in mice. Zentralblatt fur Bakteriologie, Parasitenkunde und Infectionskrankheiten 1903;34:28-34 and 122-143. Translated from German, In: Shimkin MB. Some Classics of Experimental Oncology, 50 Selections, 1775-1965 National Institutes of Health (U.S.) Publication No. 80-2150 October 1980, pp 78-105. Available from: https://babel.hathitrust.org/cgi/pt?id=mdp.39015003789719;view=1up;seq=119. [Last accessed on 30 Oct 2017]

[108] Loeb L.Ueber die Enstehung eines Sarkoms nach Transplantation eines Adenocarcinoms einer japanischen Maus..Zeitschrift für Krebsforschung1908;7:80-110. (in German)

[109] Little CC.A possible mendelian explanation for a type of inheritance apparently non-mendelian in nature..Science1914;40:904-6

[110] Strong LC.Morse HC, III.Inbred mice in science.Origins of inbred mice1978;NewYorkAcademic Press45-67

[111] Gorer PA,Snell GD.Studies on the genetic and antigenic basis of tumour transplantation: linkage between a histocompatibility gene and "fused" in mice..Proc R Soc Lond1948;135:499-505

[112] Jerne NK.The natural-selection theory of antibody formation..Proc Natl Acad Sci U S A1955;41:849-57 PMCID:PMC534292

[113] Billingham, R E, Brent, L, Medawar, PB. Quantitative studies on tissue transplantation immunity. III. Actively acquired tolerance. Available from: http://adsabs.harvard.edu/abs/1956RSPTB.239..357B. [Last accessed on 30 Oct 2017]

[114] Silverstein AM.The curious case of the 1960 Nobel Prize to Burnet and Medawar..Immunology2016;147:269-74 PMCID:PMC4754613

[115] Prehn RT.Immunity to methylcholanthrene-induced sarcomas..J Natl Cancer Inst1957;18:769-78

[116] Isaacs A.Virus interference. I. The interferon..Proc R Soc Lond B Biol Sci1957;147:258-67

[117] Porter RR.The hydrolysis of rabbit y-globulin and antibodies with crystalline papain..Biochem J1959;73:119-26 PMCID:PMC1197021

[118] Edelman GM.Studies on structural units of the gamma-globulins..J Exp Med1961;113:861-84

[119] Fleischman JB,Press EM.The arrangement of the peptide chains in gamma-globulin..Biochem J1963;88:220-8 PMCID:PMC1202100

[120] Edelman GM,Gall WE,Rutishauser U.The covalent structure of an entire gamma G immunoglobulin molecule..Proc Natl Acad Sci U S A1969;63:78-85 PMCID:PMC534037

[121] Steinman RM.Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution..J Exp Med1973;137:1142-62 PMCID:PMC2139237

[122] Zinkernagel RM.Immunological surveillance against altered self components by sensitised T lymphocytes in lymphocytic choriomeningitis..Nature1974;251:547-8

[123] Zinkernagel RM.Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system..Nature1974;248:701-2

[124] Köhler G.Continuous cultures of fused cells secreting antibody of predefined specificity..Nature1975;256:495-7

[125] Jerne NK.The somatic generation of immune recognition..Eur J Immunol1971;1:1-9

[126] Herberman RB,Holden HT.Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells..Int J Cancer1975;16:230-9

[127] Tonegawa S.Reiteration frequency of immunoglobulin light chain genes: further evidence for somatic generation of antibody diversity..Proc Natl Acad Sci U S A1976;73:203-7 PMCID:PMC335869

[128] Hozumi N.Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions..Proc Natl Acad Sci U S A1976;73:3628-32 PMCID:PMC431171

[129] Quesada JR,Manning JT,Gutterman JU.Alpha interferon for induction of remission in hairy-cell leukemia..N Engl J Med1984;310:15-8

[130] Medzhitov R,Janeway CA, Jr..A human homologue of the Drosophila Toll protein signals activation of adaptive immunity..Nature1997;388:394-7

[131] Poltorak A,Smirnova I,Van Huffel C,Birdwell D,Silva M,Freudenberg M,Layton B.Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene..Science1998;282:2085-8

[132] Shankaran V,Bruce AT,Swanson PE,Schreiber RD.IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity..Nature2001;410:1107-11

[133] Pagès F,Camus M,Costes A,Mlecnik B,Nilsson M,Meatchi T,Cugnenc PH,Fridman WH.Effector memory T cells, early metastasis, and survival in colorectal cancer..N Engl J Med2005;353:2654-66

[134] National Cancer Institute. FDA approval for Sipuleucel-T. Available from: https://www.cancer.gov/about-cancer/treatment/drugs/fda-sipuleucel-T. [Last accessed on 30 Oct 2017]

[135] Qasim W,Samarasinghe S,Amrolia P,Butler K,Wright G,Ghorashian S,Ahsan G,Lucchini G,Mifsud W,Peggs KS,Farzaneh F,Vora A,Veys P.Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells..Sci Transl Med2017;9:eaaj2013

[136] Mansh M.Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma..Yale J Biol Med2011;84:381-9 PMCID:PMC3238313

[137] U.S. Food and Drug Administration. Pembrolizumab (KEYTRUDA) Checkpoint Inhibitor. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm526430.htm. [Last accessed on 30 Oct 2017]

[138] Halpert MM,Liang D,Wing JB,Levitt JM.Dendritic cell-secreted cytotoxic T-lymphocyte-associated protein-4 regulates the T-cell response by downmodulating bystander surface B7..Stem Cells Dev2016;25:774-87 PMCID:PMC4870609

[139] U.S. Food and Drug Administration. Atezolizumab (Tecentriq). Available from: https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm525780.htm. [Last accessed on 30 Oct 2017]